Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here are two mid-cap stocks with massive growth potential and one that could be down big.
One Mid-Cap Stock to Sell:
Wynn Resorts (WYNN)
Market Cap: $10.45 billion
Founded by the former Mirage Resorts CEO, Wynn Resorts (NASDAQ:WYNN) is a global developer and operator of high-end hotels and casinos, known for its luxurious properties and premium guest services.
Why Is WYNN Risky?
- 2.1% annual revenue growth over the last two years was slower than its consumer discretionary peers
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- High net-debt-to-EBITDA ratio of 5× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $102.91 per share, Wynn Resorts trades at 23.9x forward P/E. To fully understand why you should be careful with WYNN, check out our full research report (it’s free).
Two Mid-Cap Stocks to Watch:
Medpace (MEDP)
Market Cap: $16.66 billion
Founded in 1992 as a scientifically-driven alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology, and medical device companies develop new treatments.
Why Does MEDP Catch Our Eye?
- Average organic revenue growth of 17.2% over the past two years demonstrates its ability to expand independently without relying on acquisitions
- Performance over the past five years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin increased by 6 percentage points over the last five years, giving the company more capital to invest or return to shareholders
Medpace’s stock price of $598.45 implies a valuation ratio of 32.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Aramark (ARMK)
Market Cap: $15.91 billion
From serving hot dogs at major league stadiums to managing college dining halls that feed thousands daily, Aramark (NYSE:ARMK) provides food services and facilities management to schools, healthcare facilities, businesses, sports venues, and correctional institutions across 16 countries.
Why Will ARMK Outperform?
- Market share has increased this cycle as its 12% annual revenue growth over the last five years was exceptional
- Dominant market position is represented by its $19.85 billion in revenue and gives it fixed cost leverage when sales grow
- Incremental sales significantly boosted profitability as its annual earnings per share growth of 34.5% over the last five years outstripped its revenue performance
Aramark is trading at $60.36 per share, or 23x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.